Pfizer: osteoarthritis drug meets goal in Phase III trial
(CercleFinance.com) - A Phase 3 study of Pfizer and Lilly's Tanezumab found that it relieved pain in patients with osteoarthritis, according to the companies on Wednesday.
The trial involving 698 patients showed that patients who received two doses of Tanezumab separated by eight weeks, experienced a statistically significant improvement in pain, physical function and the patients' overall assessment of their condition, compared to those receiving placebo.
In addition to osteoarthritis, Tanezumab is being evaluated for chronic low back pain and cancer pain due to bone metastases.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The trial involving 698 patients showed that patients who received two doses of Tanezumab separated by eight weeks, experienced a statistically significant improvement in pain, physical function and the patients' overall assessment of their condition, compared to those receiving placebo.
In addition to osteoarthritis, Tanezumab is being evaluated for chronic low back pain and cancer pain due to bone metastases.
Copyright (c) 2018 CercleFinance.com. All rights reserved.